Grifols SA - ADR - Level III
GRFS
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
29% downsideOvervalued by 29% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.66 Billion |
|---|---|
| Enterprise Value | $14.75 Billion |
| Dividend Yield | $0.28 (0.83%) |
| Earnings per Share | $0.57 |
| Beta | 1.18 |
| Outstanding Shares | 680,575,312 |
Return
| Return on Equity | 8.16% |
|---|---|
| Return on Assets | 2.25% |
| Return on Invested Capital | 7.45% |
Valuation & Multiples
| P/E Ratio | 22.65 |
|---|---|
| PEG | 71.77 |
| Price to Sales | 0.79 |
| Price to Book Ratio | 0.72 |
| Enterprise Value to Revenue | 1.99 |
| Enterprise Value to EBIT | 11.09 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | 0.58 |
| Debt to Equity | 1.55 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 65.54% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.61%▼ 20.47% |
|---|---|
| Total Invested | $29.39M▼ 97.44% |
| Investors Holding | 39▼ 148.00% |
ESG Score
No data
About Grifols SA
Relevant Senate Committees
Provides critical analysis and 'scoring' for all tax legislation, directly influencing corporate tax policy and capital investment incentives that profoundly impact a company's profitability.
Controls tax policy, trade agreements, and entitlement spending (e.g., Medicare/Medicaid pricing and reimbursement), all of which have profound and direct financial impacts on pharmaceutical manufacturers.
Allocates federal funding, including for health programs, scientific research (NIH), and potentially VA procurement, directly influencing the financial landscape and revenue opportunities for pharmaceutical companies.
Directly oversees the FDA, which regulates drug approval, manufacturing, and safety – core to a pharmaceutical preparation company's existence and profitability. Also influences R&D via NIH funding.
Oversees intellectual property laws (patents critical for pharma), antitrust enforcement (major for M&A and market competition), and the DOJ, all directly impacting pharmaceutical companies.